Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016)

References

• Parkinon J. Essay on the shaking palsy. London: Sherwood, Neely & Jones; 1817.
   Google Scholar
• Goldman JG, Goetz CG. History of Parkinson’s disease. In: Koller WC, Melamed E, editors. Handbook of clinical neurology. 2007;83:109.
   Google Scholar
• Jellinger KA. The pathomechanisms underlying Parkinson’s disease. Expert Rev Neurother. 2014 Feb;14(2):199–215.
   PubMed Web of Science ®Google Scholar
• Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 2002 Mar;51(3):296–301.
   PubMed Web of Science ®Google Scholar
• Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004 Nov 18;44(4):595–600.
   PubMed Web of Science ®Google Scholar
• Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004 Nov 18;44(4):601–607.
   PubMed Web of Science ®Google Scholar
• Labbe C, Ross OA. Association studies of sporadic Parkinson’s disease in the genomic era. Curr Genomics. 2014 Feb;15(1):2–10.
   PubMed Web of Science ®Google Scholar
• Liu Z, Lenardo MJ. The role of LRRK2 in inflammatory bowel disease. Cell Res. 2012 Jul;22(7):1092–1094.
   PubMed Web of Science ®Google Scholar
• Wang D, Xu L, Lv L, et al. Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China. Genes Immun. 2015 Mar;16(2):112–119.
   PubMed Web of Science ®Google Scholar
• Agalliu I, San Luciano M, Mirelman A, et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol. 2015 Jan;72(1):58–65.
   PubMed Web of Science ®Google Scholar
• Kumari U, Tan EK. LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. Febs J. 2009 Nov;276(22):6455–6463.
   PubMed Web of Science ®Google Scholar
• Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study. Lancet Neurol. 2011 Oct;10(10):898–908.
   PubMed Web of Science ®Google Scholar
• Liu M, Bender SA, Cuny GD, et al. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson’s disease-linked LRRK2 mutant G2019S. Biochemistry. 2013 Mar 12;52(10):1725–1736.
   PubMed Web of Science ®Google Scholar
• Piccoli G, Onofri F, Cirnaru MD, et al. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol Cell Biol. 2014 Jun;34(12):2147–2161.
   PubMed Web of Science ®Google Scholar
• Nichols RJ, Dzamko N, Morrice NA, et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J. 2010 Sep 15;430(3):393–404.
   PubMed Web of Science ®Google Scholar
• Steger M, Tonelli F, Ito G, et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. eLIFE. 2016;5:e12813.
   Web of Science ®Google Scholar
• Sheng Z, Zhang S, Bustos D, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med. 2012 Dec 12;4(164):164ra61.
   Web of Science ®Google Scholar
• Delbroek L, Van Kolen K, Steegmans L, et al. Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation. J Pharm Biomed Anal. 2013 Mar 25;76:49–58.
   PubMed Web of Science ®Google Scholar
• Guaitoli G, Raimondi F, Gilsbach BK, et al. Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts. Proc Natl Acad Sci USA. 2016 Jul 26;113(30):E4357–66.
   PubMed Web of Science ®Google Scholar
• Galatsis P, Henderson J, Kormos BL, et al. Development of LRRK2 kinase inhibitors for Parkinson’s disease. Annu Rep Med Chem. 2014;49:43–58.
   Web of Science ®Google Scholar
• Galatsis P, Henderson JL, Kormos BL, et al. Leucine-rich repeat kinase 2 (LRRK2) inhibitors. Top Med Chem. 2016;18:111-148.
   Google Scholar
• Galatsis P, Hayward MM, Kormos BL, et al., inventors; Pfizer Inc., USA. assignee. Preparation of novel 4-(substituted amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors patent US20140005183A1. 2014.
   Google Scholar
• Galatsis P, Hayward MM, Kormos BL, et al., inventors; Pfizer Inc., USA. assignee. Preparation of novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors patent WO2015092592A1. 2015.
   Google Scholar
• Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419–432.
   PubMed Web of Science ®Google Scholar
• Daher JP, Abdelmotilib HA, Hu X, et al. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates alpha-synuclein gene-induced neurodegeneration. J Biol Chem. 2015 Aug 7;290(32):19433–19444.
   PubMed Web of Science ®Google Scholar
• Almstetter M, Thormann M, Treml A, et al., inventors; Origenis GmbH, Germany. assignee. Preparation of heterocyclic compounds as kinase inhibitors patent WO2012143143A1. 2012.
   Google Scholar
• Almstetter M, Thormann M, Treml A, et al., inventors; Origenis GmbH, Germany. assignee. Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors and their preparation patent WO2012143144A1. 2012.
   Google Scholar
• Almstetter M, Thormann M, Treml A, et al., inventors; Origenis GmbH, Germany. assignee. Pyrazolo[4,3-d]pyrimidines as kinase inhibitors and their preparation patent WO2014060112A1. 2014.
   Google Scholar
• Almstetter M, Thormann M, Treml A, et al., inventors; Origenis GmbH, Germany. assignee. Pyrazolo[4,3-c]quinolines as kinase inhibitors and their preparation patent WO2014060113A1. 2014.
   Google Scholar
• Mikkelsen GK, David L, Watson S, et al., inventors; H. Lundbeck A/S, Den.; Vernalis R&D Ltd. assignee. Preparation of aminopyridine derived compounds as LRRK2 inhibitors patent WO2014106612A1. 2014.
   Google Scholar
• Bedford ST, Chen IJ, Wang Y, et al., inventors; H. Lundbeck A/S, Den.; Vernalis R&D Ltd. assignee. Preparation of 4,6-disubstituted 1H-pyrrolo[2,3-b]pyridine-3-carbonitrile compounds as LRRK2 inhibitors patent WO2014170248A1. 2014.
   Google Scholar
• McCauley JA, Greshock TJ, Sanders J, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. Preparation of benzothiophenone compounds inhibiting leucine-rich repeat kinase enzyme activity patent WO2012118679A1. 2012.
   Google Scholar
• McCauley JA, Rajapakse HA, Greshock TJ, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. preparation of thieno[3,4-c]pyridin-4(5H)-one derivatives as inhibitors of Leucine-rich repeat kinase patent WO2012058193A1. 2012.
   Google Scholar
• Greshock TJ, Sanders JM, Drolet RE, et al. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors. Bioorg Med Chem Lett. 2016;26(11):2631–2635.
   PubMed Web of Science ®Google Scholar
• Miller M, Basu K, Demong D, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. 3-Pyrimidinylindazole compounds as inhibitors of leucine-rich repeat kinase enzyme activity and their preparation patent WO2014137719A1. 2014.
   Google Scholar
• Miller M, Basu K, Demong D, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. 3-Pyrimidinylindazole compounds as inhibitors of leucine-rich repeat kinase enzyme activity and their preparation patent WO2014137723A1. 2014.
   Google Scholar
• Miller M, Basu K, Demong D, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. 3-Pyrimidinylindazole compounds as inhibitors leucine-rich repeat kinase enzyme activity and their preparation patent WO2014134774A1. 2014.
   Google Scholar
• Miller M, Basu K, Demong D, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. 3-Pyridinylindazole compounds as inhibitors of leucine-rich repeat kinase enzyme activity and their preparation patent WO2014137728A1. 2014.
   Google Scholar
• Miller M, Basu K, Demong D, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. 3-Pyridinylindazole compounds as inhibitors of leucine-rich repeat kinase enzyme activity and their preparation patent WO2014137725A1. 2014.
   Google Scholar
• Miller M, Basu K, Demong D, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. 3-Pyridinylindazole compounds as inhibitors of leucine-rich repeat kinase enzyme activity and their preparation patent WO2014134776A1. 2014.
   Google Scholar
• Demong D, Greshock TJ, Chang RK, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. Compounds inhibiting leucine-rich repeat kinase enzyme activity patent WO2015026683A1. 2015.
   Google Scholar
• Demong D, Miller M, Liu H, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. Compounds inhibiting leucine-rich repeat kinase enzyme activity patent WO2015073344A1. 2015.
   Google Scholar
• Dai X, Basu K, Demong D, et al., inventors; Merck Sharp & Dohme Corp., USA. assignee. Compounds inhibiting leucine-rich repeat kinase enzyme activity patent WO2016036586A1. 2016.
   Google Scholar
• Fell MJ, Mirescu C, Basu K, et al. MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther. 2015;355(3):397–409.
   PubMed Web of Science ®Google Scholar
• Volpicelli-Daley LA, Abdelmotilib H, Liu Z, et al. G2019S-LRRK2 expression augments alpha-synuclein sequestration into inclusions in neurons. J Neurosci. 2016 Jul 13;36(28):7415–7427.
   PubMed Web of Science ®Google Scholar
• Hoflack J, Blom P, Lavergne O, inventors; Ipsen Pharma S.a.S., Fr.; Oncodesign S.A. assignee. Preparation of macrocyclic compounds as LRRK2 kinase inhibitors patent WO2014140235A1. 2014.
   Google Scholar
• Hoflack J, Blom P, Lavergne O, et al., inventors; Oncodesign S.A., Fr.; Ipsen Pharma S.A.S. assignee. Preparation of macrocyclic LRRK2 kinase inhibitors useful in the treatment and/or diagnosis of neurological disorders patent WO2016042089A1. 2016.
   Google Scholar
• Garofalo A, Aubele D, inventors; Elan Pharmaceuticals, LLC, USA. assignee. Inhibitors of LRRK2 kinase activity patent WO2014150981A1. 2014.
   Google Scholar
• Shah S, Federoff HJ, inventors; Georgetown University, USA. assignee. Small molecule inhibitors of LRRK2 kinase and protein kinase ERK5 for treating cancer and neurodegenerative disorders patent WO2014160430A1. 2014.
   Google Scholar
• Chan B, Estrada A, Shore D, et al., inventors; Genentech, Inc., USA. assignee. Preparation of pyrazolopyridine compounds as LRRK2 inhibitors patent US20140288043A1. 2014.
   Google Scholar
• Feng Y, Lograsso P, inventors; The Scripps Research Institute, USA. assignee. Bidentate-binding modulators of LRRK2 and JNK kinases patent WO2014200682A1. 2014.
   Google Scholar
• Martinez Gil A, Gil Ayuso-Gontan C, Garcia Salado I, et al., inventors; Consejo Superior de Investigaciones Cientificas CSIC, Spain. assignee. Preparation of substituted isatins as leucine-rich repeats LRRK2 inhibitors for treating neurodegenerative diseases patent WO2015150612A1. 2015.
   Google Scholar
• Ding X, Liu Q, Long K, et al., inventors; GlaxoSmithKline Intellectual Property Development Limited, UK; GlaxoSmithKline China R&D Company Limited. assignee. Preparation of heterocycles as LRRK2 kinase inhibitors patent WO2015113451A1. 2015.
   Google Scholar
• Ding X, Liu Q, Sang Y, et al., inventors; GlaxoSmithKline Intellectual Property Development Limited, UK; GlaxoSmithKline China R&D Company Limited. assignee. Pyrrolo[2,3,d]piperidin-2-amine derivatives as LRRK2 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of Parkinson’s disease patent WO2015113452A1. 2015.
   Google Scholar
• Kim SW, Kim JH, Choi JS, et al., inventors; Oscotec, Inc., S. Korea. assignee. Pyridopyrimidine derivatives as protein kinase LRRK2 inhibitors patent KR2016035411A. 2016.
   Google Scholar
• Cox TF, Cox MAA. Multidimensional scaling. 2nd ed. Boca Raton: Chapman & Hall/CRC; 2000.
   Google Scholar
• Fuji RN, Flagella M, Baca M, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med. 2015 Feb 4;7(273):273ra15.
   PubMed Web of Science ®Google Scholar
• Miklavc P, Ehinger K, Thompson KE, et al. Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis. Plos One. 2014;9(1):e84926.
   PubMed Web of Science ®Google Scholar
• Baptista MA, Merchant KM, Bharghava S, et al. LRRK2 kinase inhibitors of different structural classes induce abnormal, but reversible, accumulation of lamellar bodies in type II pneumocytes in non-human primates. Society for Neurosciene. 2015; Chicago, Abstract 763.02/B103.
   Google Scholar
• Wager TT, Hou X, Verhoest PR, et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci. 2010 Jun 16;1(6):435–449.
   PubMed Web of Science ®Google Scholar
• Wager TT, Hou X, Verhoest PR, et al. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem Neurosci. 2016 Jun 15;7(6):767–775.
   PubMed Web of Science ®Google Scholar